373 related articles for article (PubMed ID: 15113815)
21. Prognostic and predictive value of HER2/neu oncogene in breast cancer.
Masood S; Bui MM
Microsc Res Tech; 2002 Oct; 59(2):102-8. PubMed ID: 12373720
[TBL] [Abstract][Full Text] [Related]
22. [HER-2 overexpression and gene amplification of advanced breast cancers determined by fluorescence in situ hybridization in fine needle aspiration specimens].
Zhang Z; Zhao L; Guo H; Guo L; Ling Y; Xu X; Zhao H; Pan Q
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):183-7. PubMed ID: 24785277
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Lara PN; Chee KG; Longmate J; Ruel C; Meyers FJ; Gray CR; Edwards RG; Gumerlock PH; Twardowski P; Doroshow JH; Gandara DR
Cancer; 2004 May; 100(10):2125-31. PubMed ID: 15139054
[TBL] [Abstract][Full Text] [Related]
24. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
25. Detection of HER-2/neu (c-erbB-2) overexpression and amplification in breast carcinomas with ambiguous immunohistochemical results. A further contribution to defining the role of fluorescent in situ hybridization.
Sidoni A; Ferri I; Cavaliere A; Bellezza G; Scheibel M; Bucciarelli E
Anticancer Res; 2006; 26(3B):2333-7. PubMed ID: 16821612
[TBL] [Abstract][Full Text] [Related]
26. HER-2 status determination in breast carcinomas. A practical approach.
García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M
Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244
[TBL] [Abstract][Full Text] [Related]
27. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Press MF; Sauter G; Bernstein L; Villalobos IE; Mirlacher M; Zhou JY; Wardeh R; Li YT; Guzman R; Ma Y; Sullivan-Halley J; Santiago A; Park JM; Riva A; Slamon DJ
Clin Cancer Res; 2005 Sep; 11(18):6598-607. PubMed ID: 16166438
[TBL] [Abstract][Full Text] [Related]
29. High-quality HER-2 testing: setting a standard for oncologic biomarker assessment.
Wiley EL; Diaz LK
JAMA; 2004 Apr; 291(16):2019-20. PubMed ID: 15113823
[No Abstract] [Full Text] [Related]
30. Fluorescence in situ hybridization for HER-2/neu amplification of breast carcinoma in archival fine needle aspiration biopsy specimens.
Gu M; Ghafari S; Zhao M
Acta Cytol; 2005; 49(5):471-6. PubMed ID: 16334021
[TBL] [Abstract][Full Text] [Related]
31. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing.
Vanden Bempt I; Van Loo P; Drijkoningen M; Neven P; Smeets A; Christiaens MR; Paridaens R; De Wolf-Peeters C
J Clin Oncol; 2008 Oct; 26(30):4869-74. PubMed ID: 18794552
[TBL] [Abstract][Full Text] [Related]
32. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
[TBL] [Abstract][Full Text] [Related]
33. Her-2/neu and breast cancer.
Kaptain S; Tan LK; Chen B
Diagn Mol Pathol; 2001 Sep; 10(3):139-52. PubMed ID: 11552716
[TBL] [Abstract][Full Text] [Related]
34. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
35. [Detection of HER-2/neu in breast carcinoma].
Skálová A; Vanĕcek T; Losan F; Papoutsidesová ; Fínek J
Cas Lek Cesk; 2003 Feb; 142(2):93-8. PubMed ID: 12698536
[TBL] [Abstract][Full Text] [Related]
36. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy.
Diaz NM
Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337
[TBL] [Abstract][Full Text] [Related]
37. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
38. Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients.
Kokate P; Sawaimoon S; Bhatia S; Mandava S
Genet Test Mol Biomarkers; 2012 Apr; 16(4):239-45. PubMed ID: 22023243
[TBL] [Abstract][Full Text] [Related]
39. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study.
Persons DL; Bui MM; Lowery MC; Mark HF; Yung JF; Birkmeier JM; Wong EY; Yang SJ; Masood S
Ann Clin Lab Sci; 2000 Jan; 30(1):41-8. PubMed ID: 10678582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
